GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials.

中文翻译：

---

GLP-1 受体激动剂对肾脏和心血管疾病结局的影响：随机对照试验的荟萃分析


GLP-1 受体激动剂可降低主要不良心血管事件 （MACE） 的风险，并且还可以对肾脏有益。然而，GLP-1 受体激动剂是否能改善临床上重要的肾脏结局仍不确定。我们旨在通过对随机对照试验进行荟萃分析，全面评估 GLP-1 受体激动剂对肾脏和心血管疾病结局的影响。